Literature DB >> 12242131

Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome?

Filip Claus1, Tom Boterberg, Piet Ost, Wilfried De Neve.   

Abstract

Intensity modulated radiation therapy (IMRT) was given for 32 patients with M0 sinonasal cancer, with a median follow-up of 15 months. Acute toxicity was mucositis grades 1-2 in 28 patients and grade 3 in four patients. No corneal injury was observed, except in one patient where it was present before the start of IMRT. Conjunctivitis and dry eye symptoms were mild (no grade 3-4 toxicity) and no evolution to dry eye syndrome was observed. We conclude that high dose conformality of IMRT results in mild acute toxicity and that IMRT allows avoiding dry eye syndrome by its ability to create concave dose distributions which avoid the main lacrimal glands. Follow-up it too short to evaluate local control, optic nerve or retinal toxicity.

Entities:  

Mesh:

Year:  2002        PMID: 12242131     DOI: 10.1016/s0167-8140(02)00172-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Outcome and toxicity of intensity-modulated radiotherapy with simultaneous integrated boost in patients with pharyngo-laryngeal cancer.

Authors:  A Fondevilla Soler; J L López-Guerra; A García Fernández; M A Samaniego Conde; M J Belmonte González; J M Praena-Fernandez; E Rivin Del Campo; M Alcaraz; I Azinovic
Journal:  Clin Transl Oncol       Date:  2018-11-30       Impact factor: 3.405

2.  Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity-modulated radiation therapy.

Authors:  Jessica A Lawrence; Lisa J Forrest; Michelle M Turek; Paul E Miller; T Rockwell Mackie; Hazim A Jaradat; David M Vail; Richard R Dubielzig; Richard Chappell; Minesh P Mehta
Journal:  Vet Radiol Ultrasound       Date:  2010 Sep-Oct       Impact factor: 1.363

3.  IMRT and IGRT in head and neck cancer: Have we delivered what we promised?

Authors:  Gupta Tejpal; Agarwal Jaiprakash; Bannerjee Susovan; Sarbani Ghosh-Laskar; Vedang Murthy; Ashwini Budrukkar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

4.  Feasibility of tomotherapy for Graves' ophthalmopathy: Dosimetry comparison with conventional radiotherapy.

Authors:  Nam P Nguyen; Shane P Krafft; Paul Vos; Vincent Vinh-Hung; Misty Ceizyk; Siyoung Jang; Anand Desai; Dave Abraham; Lars Ewell; Christopher Watchman; Russ Hamilton; Beng-Hoey Jo; Ulf Karlsson; Lexie Smith-Raymond
Journal:  Strahlenther Onkol       Date:  2011-06-28       Impact factor: 3.621

Review 5.  New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.

Authors:  Nancy Y Lee; Quynh-Thu Le
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

6.  Radionecrosis of the frontal lobe as a consequence of malignant ethmoid tumor management: incidence, diagnosis, risk factors, prevention and management.

Authors:  N Oker; P Lang; D Bresson; B George; J-P Guichard; M Wassef; E Sauvaget; S Froelich; R Kania; P Herman
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-16       Impact factor: 2.503

7.  Clinical-dosimetric relationship between lacrimal gland dose and ocular toxicity after intensity-modulated radiotherapy for sinonasal tumours.

Authors:  S S Batth; R Sreeraman; E Dienes; L A Beckett; M E Daly; J Cui; M Mathai; J A Purdy; A M Chen
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

Review 8.  Intensity-modulated radiation therapy for head and neck cancer.

Authors:  Gokhan Ozyigit; Thomas Yang; K S Clifford Chao
Journal:  Curr Treat Options Oncol       Date:  2004-02

9.  Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes.

Authors:  Stephanie E Combs; Stephan Konkel; Daniela Schulz-Ertner; Marc W Münter; Jürgen Debus; Peter E Huber; Christoph Thilmann
Journal:  Radiat Oncol       Date:  2006-07-21       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.